@article{b728e28f1afb4b5d88857b0965b9435b,
title = "A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma",
abstract = "Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/refractory Hodgkin lymphoma (HL). However, no large studies have evaluated pretransplant factors predictive of outcomes of AutoHCT in children, adolescents and young adults (CAYA, age <30 years). In a retrospective study, we analyzed 606 CAYA patients (median age 23 years) with relapsed/refractory HL who underwent AutoHCT between 1995 and 2010. The probabilities of PFS at 1, 5 and 10 years were 66% (95% confidence interval (CI): 62-70), 52% (95% CI: 48-57) and 47% (95% CI: 42-51), respectively. Multivariate analysis for PFS demonstrated that at the time of AutoHCT patients with Karnofsky/Lansky score ≥90, no extranodal involvement and chemosensitive disease had significantly improved PFS. Patients with time from diagnosis to first relapse of <1 year had a significantly inferior PFS. A prognostic model for PFS was developed that stratified patients into low-, intermediate- and high-risk groups, predicting for 5-year PFS probabilities of 72% (95% CI: 64-80), 53% (95% CI: 47-59) and 23% (95% CI: 9-36), respectively. This large study identifies a group of CAYA patients with relapsed/refractory HL who are at high risk of progression after AutoHCT. Such patients should be targeted for novel therapeutic and/or maintenance approaches post-AutoHCT.",
author = "P. Satwani and Ahn, {K. W.} and J. Carreras and H. Abdel-Azim and Cairo, {M. S.} and A. Cashen and Chen, {A. I.} and Cohen, {J. B.} and Costa, {L. J.} and C. Dandoy and Fenske, {T. S.} and Freytes, {C. O.} and S. Ganguly and Gale, {R. P.} and N. Ghosh and Hertzberg, {M. S.} and Hayashi, {R. J.} and Kamble, {R. T.} and Kanate, {A. S.} and A. Keating and Kharfan-Dabaja, {M. A.} and Lazarus, {H. M.} and Marks, {D. I.} and T. Nishihori and Olsson, {R. F.} and Prestidge, {T. D.} and Rolon, {J. M.} and Savani, {B. N.} and Vose, {J. M.} and Wood, {W. A.} and Inwards, {D. J.} and V. Bachanova and Smith, {S. M.} and Maloney, {D. G.} and A. Sureda and M. Hamadani",
note = "Funding Information: We thank the patients and centers reporting to CIBMTR and CIBMTR Lymphoma. We also thank the following committee members for their scientific input: Baldeep Wirk, Basem M William, Harry C Schouten, Nishitha M Reddy, David Rizzieri, Mahmoud Aljurf, Reinhold Munker, Brandon Hayes-Lattin, Victor A Lewis, and Maggie M Simaytis for administrative support. The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-12-1-0142 and N00014-13-1-0039 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals; Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America, Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc.; Roswell Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon Children{\textquoteright}s Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.; Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St Baldrick{\textquoteright}s Foundation; StemCyte, A Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS, Inc.; University of Minnesota; University of Utah; and *Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the US Government. *Corporate Members. Publisher Copyright: {\textcopyright} 2015 Macmillan Publishers Limited. All rights reserved.",
year = "2015",
month = nov,
day = "1",
doi = "10.1038/bmt.2015.177",
language = "English (US)",
volume = "50",
pages = "1416--1423",
journal = "Bone marrow transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "11",
}